

**Additional information under art. 33, par. 1, item 6 of
Ordinance № 2 from 17 September 2003 of "Sopharma" AD as at
31 December 2012**

1. Information about changes in accounting policies during the reporting period, the reasons for them and how they affect the financial results and equity of the issuer – For the current financial year the Company has adopted all new and / or revised standards and interpretations issued by the International Accounting Standards Board (IASB), respectively. The Interpretations Committee of the IFRS, which are relevant to its operations. More detailed information about the Company's accounting policies can be found at 2.1. Basis of preparation of the financial statements for 2012 in the notes to the interim financial statement for the fourth quarter.

2. Information about changes in the economic group of the issuer, if such a group is present:

- Rostbalkanpharm AD. – the shares of the company were sold on 10 April 2012;
- Sopharma Ukraine EOOD - date of acquisition- 7 August 2012;
- Sopharma Zdrovit AD - the company is in the process of liquidatio;
- Sopharma Poland OOD - the company is in the process of liquidation.

3. Information about the results of organizational changes within the issuer, such as restructuring, sale of companies from the group, in-kind contributions from companies, rental property, long-term investments, closure of business.

The book value of the investments in subsidiaries is as follows:

		31.12.2012	Interest	31.12.2011	Interest
		BGN '000	%	BGN '000	%
Sopharma Trading AD	Bulgaria	32 148	81.01	32 273	81.33
Unipharm AD	Bulgaria	19 449	49.99	19 449	49.99
Bulgarian Rose Sevtopolis AD	Bulgaria	8 729	49.99	8 729	49.99
Biopharm Engineering AD	Bulgaria	8 474	97.15	3 451	69.43
Briz OOD	Latvia	6 262	51.00	6 262	51.00
Vitamina AD	Ukraine	6 187	99.56	6 187	99.56
Ivanchich and sons	Serbia	5 739	51.00	5 739	51.00
Momina Krepost AD	Bulgaria	2 796	49.94	2 891	49.85
Pharmalogistica AD	Bulgaria	1 911	76.54	1 911	76.54
Sopharma Buildings REIT	Bulgaria	828	42.64	1 128	42.64
Electroncommerce EOOD	Bulgaria	384	100.00	384	100.00
Sopharma Warsaw EOOD	Poland	323	100.00	7	100.00
Sopharma Ukraine EOOD	Ukraine	230	100.00	-	-
Rostbalkanpharm AD	Russia	-	51.00	4	51.00
Sopharma Zdrovit EOOD	Poland	-	50.01	-	50.01
Sopharma Poland OOD	Poland	-	60.00	-	60.00
Extab Corporation	USA	-	80.00	47	80.00
Sopharma USA	USA	-	100.00	-	100.00
		93 460		88 462	

Sopharma has direct or indirect control over the above listed companies.

The *available-for-sale investments* (financial assets) at carrying amount include the participation (shares) in the following companies:

	31.12.2012	Interest	31.12.2011	Interest
	BGN '000	%	BGN '000	%
Doverie United Holding AD	14 066	18.70	12 870	14.86
Medica AD	2 245	10.20	2 420	10.13
Olainfarm AD - Latvia	1 078	0.77	703	0.77
Lavena AD	416	4.88	426	4.99
Hydroizomat AD	372	9.33	51	3.74
Maritzatex AD	269	6.20	146	3.68
Sopharma Properties AD	210	0.63	115	0.36
Todorov AD	46	4.97	46	4.97
Ecobulpack AD	7	1.48	7	1.48
UniCredit Bulbank AD	3	0.001	3	0.001
Bulgarian Stock Exchange – Sofia AD	-	-	4	0.03
Aroma AD	-	-	1	0.03
Total	<u>18 712</u>		<u>16 792</u>	

All aforementioned companies except for Olainfarm AD, Latvia, have their seat and operations in Bulgaria.

4. Opinion of the governing body regarding the feasibility of the published estimates of the results for the current financial year, taking into account the results of the current quarter as well as information on the factors and circumstances that will affect the achieving of the projected results for at least the next quarter - *no update of the forecast results*.

5. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;

SHAREHOLDERS	Number of	Number of
	shares /%/	shares /%/
	31 December	31 September
	2012	2012
„Donev Investment Holding” AD, EIK 0831915121, Sofia, Positano Str. № 12	32 373 781 /24,53%/	32 443 391 /24,58%/
“Telecomplect Invest” AD, EIK 201653294, Sofia, Totleben Blvd. № 69-73, floor 4	26 948 052 /20,42%/	26 948 052 /20,42%/
„Finance Consulting Company” EOOD EIK 121414242 Sofia, Khan Krum Str. 10	18 213 990 /13,80%/	21 437 242 /16,24%/
Universal Pension Fund “Doverie” AD, EIK 130474628 Sofia, Dunav Str. 5	8 877 397 /6,73%/	8 871 943 /6,72%/

6. For public companies - data on persons holding directly or indirectly at least 5 percent of the voting rights of the General Meeting at the end of the quarter, and changes in ownership of those voting rights since the end of the preceding quarter;...

Members of the Board of Directors	Number of shares	Number of shares
	31 December 2012	31 September 2012
1. Ognian Ivanov Donev	0	0
2. Vessela Liubenova Stoeva	0	0
3. Andrey Liudmilov Breshkov	0	0
4. Ognian Kirilov Palaveev	54320	54320
5. Alexander Viktorov Chaushev	86514	86514

7. No information on pending judicial, administrative or arbitration proceedings relating to liabilities or receivables amounting to at least 10 percent of the equity of the Company.

8. Information on loans granted by the issuer or their subsidiary, provided guarantees or commitments to a single person or a subsidiary thereof, including to related persons with indication of the nature of the relationship between the issuer and the person, the amount of the outstanding principal, the interest rate, the maturity, the size of commitment, the terms and conditions.

Long-term loans granted to related parties are as follows:

	31.12.2012	31.12.2011
	BGN '000	BGN '000
Companies under a common control through key managing personnel	748	729
Subsidiaries	-	15 340
Total	748	16 069

The terms and conditions of the long-term loans granted to related parties are as follows:

Currency	Contracted amount '000	Maturity	Interest %	30. September 2012		31 December 2011	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
<i>to Companies under common indirect control through key managing personnel</i>							
BGN	1 100	31.12.2014	8.08%	748	25	729	1
<i>to subsidiaries</i>							
USD	3 000	25.01.2015	9.80%	-	-	1 741	381
EUR	2 770	21.01.2013	6.10%	-	-	5 845	1 311
USD	1 000	25.01.2015	9.80%	-	-	5 732	314
USD	3 000	25.01.2015	9.80%	-	-	2 022	510
				748	25	16 069	2 517

The long-term loans granted to related parties are not secured by collateral.

Loans granted to related parties by type of related party are as follows:

	31.12.2012 BGN '000	31.12.2011 BGN '000
Receivables from companies under common control through key managing personnel	39 324	36 088
Companies – main shareholders	8 170	14 458
Companies under common indirect control	13 078	12 737
Impairment of trade loans	(1 958)	(1 783)
	11 120	10 954
Subsidiaries	6 407	267
Total	65 021	61 767

The terms of the granted loans to related companies are as follows:

Currency	Contracted amount '000	Maturity	Interest %	31.12.2012		31.12.2011	
				BGN'000	BGN'000 including interest	BGN'000	BGN'000 including interest
<i>to companies under common indirect control through key managing personnel</i>							
BGN	18 478	31.12.2013	8.30%	14 932	324	14 492	662
EUR	8 630	31.12.2013	4.50%	12 302	106	14 164	82
BGN	25 550	31.08.2013	8.08%	11 353	35	-	-
BGN	1 300	31.12.2013	8.08%	510	9	53	3
BGN	190	31.12.2013	8.08%	227	37	211	21
EUR	1 581	31.12.2012	5.50%	-	-	3 387	295
BGN	2 477	31.12.2012	8.08%	-	-	2 669	288
BGN	945	31.12.2012	8.08%	-	-	1 011	211
BGN	120	10.07.2012	8.08%	-	-	101	-
<i>to companies – main shareholders</i>							
EUR	4 035	31.12.2013	4.80%	8 170	278	7 991	99
BGN	18 495	31.08.2012	8.08%	-	-	6 467	-
<i>to companies under common indirect control</i>							
EUR	7 556	31.12.2013	4.50%	10 010	-	10 604	-
BGN	1 375	31.12.2013	8.08%	1 110	-	350	-
<i>to subsidiaries</i>							
EUR	2 770	20.01.2013	6.10%	6 062	645	-	-
USD	110	31.12.2013	3.50%	167	4	45	-
BGN	600	31.12.2013	7.00%	101	-	151	1
USD	25	31.12.2013	3.50%	39	2	39	1
USD	20	31.12.2013	3.50%	32	3	32	2
EUR	3	07.11.2013	13.00%	6	-	-	-
				65 021	1 443	61 767	1 665

As at 31 December 2012 there are pledges on receivables from related parties amounting to 10,500 thousand BGN (31 December 2011: 10,450 thousand BGN) as collateral for bank loans. (Notes № 27 and № 30).

Ognian Donev, PhD
Executive Director